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OBJECTIVE — We sought to assess the associations of testosterones and sex hormone–
binding globulin (SHBG) with metabolic syndrome and insulin resistance in men.
RESEARCH DESIGN AND METHODS — We deﬁned metabolic syndrome according
to the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and
TreatmentofHighBloodCholesterolinAdults.Amongmenaged20yearswhoparticipatedin
the Third National Health and Nutrition Examination Survey (n  1,226), the Cox proportional
hazards model was used to estimate the prevalence ratio and 95% CI of metabolic syndrome
according to circulating concentrations of testosterones and SHBG.
RESULTS — Afteradjustmentforage,race/ethnicity,smokingstatus,alcoholintake,physical
activitylevel,LDLcholesterol,C-reactiveprotein,andinsulinresistance,menintheﬁrstquartile
(lowest) (prevalence ratio 2.16 [95% CI 1.53–3.06]) and second quartile of total testosterone
(2.51[1.86–3.37])weremorelikelytohavemetabolicsyndromethanmeninthefourthquartile
(highest,referentgroup)(P0.001forlineartrend).Similarly,menintheﬁrstquartileofSHBG
(2.17[1.32–3.56])weremorelikelytohavemetabolicsyndromethanmeninthefourthquartile
(P  0.02 for linear trend). No signiﬁcant associations of calculated free testosterone (P  0.31
for linear trend) and bioavailable testosterone (P  0.11 for linear trend) with metabolic syn-
drome were detected after adjustment for all possible confounders.
CONCLUSIONS — Low concentrations of total testosterone and SHBG were strongly asso-
ciated with increased likelihood of having metabolic syndrome, independent of traditional
cardiovascular risk factors and insulin resistance.
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T
estosterone, synthesized and pro-
duced by the Leydig cells of the tes-
tes,isthepredominantsexhormone
in men. Sex hormone–binding globulin
(SHBG), produced by the liver, is a circu-
lating steroid-transporting protein. In the
general circulation, total testosterone is
currently classiﬁed into four major frac-
tions: SHBG-bound testosterone (44%),
albumin-bound testosterone (50%),
cortisol-binding globulin–bound testos-
terone (4%), and unbound or free tes-
tosterone (2%) (1). Free and albumin-
bound testosterones are thought to be
readily available to the tissues of the body
(i.e., bioavailable testosterone). Aging
men are characterized by a decrease in
circulating testosterone concentrations
(2), and testosterone deﬁciency (or late-
onsethypogonadismorandropause),and
low SHBG levels have been associated
with increased risk of type 2 diabetes (3).
Insulin resistance is known to be
closely related to both metabolic syn-
drome (4) and sex hormone concentra-
tions(5).Recently,severalcross-sectional
studies (6–8) have also linked low levels
of testosterone and SHBG to metabolic
syndrome or its speciﬁc components. A
few prospective studies have investigated
thedirectrelationshipsbetweentestoster-
oneandSHBGaspredictorsfortheriskof
metabolic syndrome (9–11). However,
previous studies have been limited by the
lack of comprehensive assessment of in-
sulin resistance and free testosterone lev-
els and the lack of generalizability due to
their focus on special populations such as
patients with sexual dysfunction or par-
ticipants in restricted geographic areas.
To further assess the role of testosterone
and SHBG in relation to metabolic syn-
drome and insulin resistance in the gen-
eral population, we analyzed data from
the Third National Health and Nutrition
Examination Survey (NHANES III), in
whichallthesemeasureswereavailablein
this nationally representative sample of
men in the U.S.
RESEARCH DESIGN AND
METHODS— A representative sam-
ple of the civilian noninstitutionalized
U.S. population was recruited into
NHANES III (1988–1994) with a multi-
stage, stratiﬁed sampling design (12).
NHANES III oversampled non-Hispanic
blacks, Mexican Americans, and adults
aged 60 years to ensure enough data
and reliable estimates in these subpopu-
lations. Response rates were 86% for the
household interviews and 78% for the
medical examinations. Blood was drawn
after an overnight fast for participants
in the morning sample. After centrifuga-
tion, serum samples were aliquotted and
stored at 70°C until they were quanti-
ﬁed. The serum samples were shipped on
dry ice directly to the assay laboratory. In
the present study, NHANES III Survey
Phase I (1988–1991) data (n  1,470
men aged 20 years) were analyzed. Af-
ter exclusion of participants who had
fasted 8h( n  101) and had missing
data on all covariates (n  143), the ana-
lytic sample (n  1,226, 83.4%) com-
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297 non-Hispanic blacks (9.5%), 307
Mexican Americans (5.1%), and 49 par-
ticipants with all other race/ethnicity
(7.5%).
Measurements
Sex steroid hormone concentrations.
Serum concentrations of total testoster-
one and SHBG were measured using
competitive electrochemiluminescence
immunoassays on the Elecsys 2010 auto-
analyzer (Roche Diagnostics, Indianapo-
lis, IN). The lowest detection limits of the
assays were 0.02 ng/ml for total testoster-
one and 3 nmol/l for SHBG. The coefﬁ-
cients of variation were 5.9 and 5.8% at
2.5 and 5.5 ng/ml for total testosterone
and 5.3 and 5.9% at 5.3 and 16.6 nmol/l
for SHBG. Detailed laboratory methods,
quality-control procedures, and mean
concentrations of testosterone and SHBG
have been reported previously (13). Cal-
culatedfreetestosterone(CFT)andcalcu-
lated bioavailable testosterone (CBT)
concentrationswereobtainedfromserum
total testosterone, SHBG, and albumin
concentrations using the methods pro-
posed by Vermeulen et al. (14).
Measures of metabolic syndrome com-
ponents and other biochemical mark-
ers. Waist circumference of participants
wasmeasuredatthehighpointoftheiliac
crest at minimal respiration to the nearest
0.1 cm. Averages of the second and the
thirdsystolicbloodpressureanddiastolic
blood pressure readings were used in the
analyses. Serum total cholesterol was
measuredenzymaticallyinaseriesofcou-
pled reactions that hydrolyze cholesterol
estersandoxidizethe3-hydroxygroupof
cholesterol. Serum triglycerides were
measured enzymatically after hydrolysis
to produce glycerol. The HDL cholesterol
concentration was measured after precip-
itation of the other lipoproteins with a
polyanion/divalent cation mixture. Total
cholesterol,triglyceride,andHDLcholes-
terol analyses were performed by the
Hitachi 704 Analyzer (Boehringer Mann-
heim Diagnostics, Indianapolis, IN). The
plasma glucose concentration was mea-
sured by using an enzymatic reaction
(Cobas Mira Chemistry System; Roche
Diagnostic Systems, Montclair, NJ). LDL
cholesterol concentration was calculated
by the Friedewald equation as follows:
LDL cholesterol  total cholesterol 
HDL  triglyceride/5 for participants
with a triglyceride concentration 400
mg/dl.C-reactiveprotein(CRP)wasmea-
sured by using latex-enhanced nephe-
lometry(BehringDiagnostics,Somerville,
NJ).
Deﬁnition of metabolic syndrome. Ac-
cording to the National Cholesterol Educa-
tion Program’s Adult Treatment Panel III
guidelines(15),menareconsideredtohave
metabolic syndrome if they have 3o ft h e
following 5 criteria: 1) abdominal obesity
(waistcircumference102cm),2)concen-
tration of triglycerides 150 mg/dl (1.7
mmol/l), 3) concentration of HDL choles-
terol 40 mg/dl (1.02 mmol/l), 4) systolic
blood pressure 130 mmHg or diastolic
bloodpressure85mmHg),and5)fasting
glucose level 100 mg/dl (5.6 mmol/l). In
addition, individuals currently using pre-
scribed medicine to treat hypertension are
counted as having high blood pressure;
thoseusingantidiabeticmedication(i.e.,in-
sulin or oral agents) are considered to have
diabetes.
Fasting serum insulin and homeostasis
model assessment of insulin resis-
tance. Plasma insulin concentration was
measuredbyusinganinsulinradioimmu-
noassaykit(PharmaciaDiagnostics,Upp-
sala, Sweden). The homeostasis model
assessment (HOMA) has been shown to
beareliableestimateforinsulinresistance
(HOMA-IR) and is calculated as follows:
HOMA-IR  (glucose [millimoles per li-
ter]  insulin [microunits per milliliter])/
22.5 (16). Concentrations of fasting
insulin and HOMA-IR were transformed
by natural logarithm to approximate nor-
mal distributions before they were ana-
lyzed in linear regression models.
Demographic, lifestyle, and behavioral
covariates. Demographic covariates in-
cluded age (in years) and race/ethnicity
(i.e., white, African American, Mexican
American, and other). Smoking status
wasdeterminedascurrentsmokers,former
smokers (have smoked at least 100 ciga-
rettes during their entire life but did not
smoke at the interview), and never smok-
ers. Alcohol intake was the sum of the
frequenciesofbeer,wine,andhardliquor
intake per month reported by partici-
pants. BMI was calculated by using mea-
Table 1—Geometric means of fasting serum insulin and HOMA-IR by the quartiles of total
testosterone, SHBG, CFT, and CBT in U.S. men >20 years of age, NHANES III Phase I,
1988–1991
n
Geometric mean (95% CI)*
Fasting serum insulin HOMA-IR
Total testosterone (nmol/l)
1st quartile (0.2–14.2) 351 10.59 (9.49–11.83) 2.73 (2.42–3.08)
2nd quartile (14.2–18.2) 308 10.61 (9.88–11.40) 2.62 (2.43–2.83)
3rd quartile (18.2–22.9) 289 7.18 (6.54–7.88) 1.74 (1.58–1.92)
4th quartile (22.9–47.0) 278 6.98 (6.43–7.58) 1.68 (1.54–1.83)
P value 0.001 0.001
SHBG (nmol/l)*
1st quartile (9.7–25.2) 259 10.70 (9.54–11.99) 2.71 (2.38–3.08)
2nd quartile (25.2–34.6) 292 9.60 (8.82–10.45) 2.41 (2.20–2.65)
3rd quartile (34.6–47.1) 299 7.90 (7.41–8.42) 1.93 (1.80–2.06)
4th quartile (47.1–198.3) 376 6.90 (6.32–7.55) 1.65 (1.51–1.81)
P value† 0.001 0.001
CFT (nmol/l)‡
1st quartile (0.0–0.3) 397 9.74 (8.56–11.10) 2.40 (2.07–2.78)
2nd quartile (0.3–0.4) 279 9.29 (8.63–9.99) 2.32 (2.14–2.51)
3rd quartile (0.4–0.5) 255 8.38 (7.63–9.20) 2.06 (1.86–2.28)
4th quartile (0.5–1.1) 295 7.59 (6.64–8.67) 1.87 (1.61–2.16)
P value 0.02 0.02
CBT (nmol/l)‡
1st quartile (0.0– 6.4) 412 9.85 (8.52–11.38) 2.42 (2.05–2.86)
2nd quartile (6.5– 8.7) 294 9.23 (8.61–9.88) 2.32 (2.15–2.50)
3rd quartile (8.7–11.0) 247 8.28 (7.48–9.17) 2.04 (1.83–2.26)
4th quartile (11.0–24.0) 273 7.51 (6.46–8.72) 1.83 (1.55–2.17)
P value 0.02 0.03
Data are geometric means (95% CI) of fasting serum insulin and HOMA-IR, adjusted for age, race, smoking
status, alcohol intake, physical activity level, LDL cholesterol, and CRP. *To convert nanomoles per liter to
nanograms per milliliter, divide by 3.4. †P values were estimated in the t test of deviation from linear trend
forfastingseruminsulinandHOMA-IR.‡EstimatedaccordingtothemethodsproposedbyVermeulenetal.
(14).
Li and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 7, JULY 2010 1619sured weight in kilograms divided by the
square of height in meters. Physical activ-
ity level was determined by participants’
self-reported frequency of engaging in
speciﬁc types of leisure-time exercise or
activities during the past month multi-
plied by the rate of energy expenditure
(intensity rating) according to a standard-
ized coding method (17).
Statistical analysis
First, we estimated mean concentrations
of total testosterone, SHBG, CFT, and
CBTbyageandtheircorrelationswiththe
logarithmic values of fasting insulin con-
centration and HOMA-IR. Second, we
estimated the adjusted mean concentra-
tionsoflogarithmicvaluesoffastinginsu-
lin and HOMA-IR in multivariable linear
regressionmodelsandcalculatedthegeo-
metric means by taking the exponentia-
tion of the adjusted means and their 95%
CIs to facilitate interpretation of the re-
sults. Third, we estimated the unadjusted
prevalence of metabolic syndrome by the
quartiles of the four sex hormone mea-
sures. The quartiles of the sex hormone
variables were determined according to
the weighted distributions of their origi-
nalvalues.Fourth,weestimatedtheprev-
alence ratios and 95% CI of metabolic
syndrome for testosterones and SHBG as
continuous variables and categorical vari-
ables using Cox proportional hazards
models. The continuous testosterone and
SHBG variables were transformed by nat-
ural logarithm and were standardized
withthemeanof0andSDof1tofacilitate
comparisons across the four sex hormone
measures. The estimates for the associa-
tion between sex hormones and meta-
bolic syndrome were adjusted in three
models: 1) for age, 2) for age and addi-
tional demographic characteristics and
cardiovascular risk factors, and 3) for
HOMA-IR or fasting serum insulin con-
centration in addition to all covariates in
2. Finally, we estimated the prevalence
ratio and 95% CI of the sex hormones
for the ﬁve single metabolic syndrome
components.
The t test and 
2 test were used to
assess the differences in the mean values
of continuous variables and the differ-
ences in the proportion of categorical
variables for men with and without met-
abolic syndrome. Results with P  0.05
were considered to be statistically signiﬁ-
cant for two-sided tests. All analyses were
conducted with SUDAAN software (re-
lease 9.0; Research Triangle Institute, Re-
search Triangle Park, NC) to account for
thecomplexsamplingdesignofNHANES
III. All results were weighted to represent
the U.S. population.
RESULTS— Fasting insulin (in a nat-
ural log scale) was signiﬁcantly correlated
with total testosterone (r  0.41),
SHBG (r  0.28), CFT (r  0.22),
and CBT (r  0.24) (all P  0.0001).
Similarly, HOMA-IR (in a natural log
scale)wassigniﬁcantlycorrelatedwithto-
tal testosterone (r  0.42), SHBG (r 
0.25), CFT (r  0.26), and CBT (r 
0.28) (all P  0.0001).
After adjustment for potential con-
founding effects, the geometric means of
Figure1—Unadjustedandadjustedprevalenceofthemetabolicsyndromebyquartilesforlevelsoftotaltestosterone(TT)(A),SHBG(B),CFT(C),
andCBT(D)inU.S.men20yearsofage,NHANESIII,PhaseI,1988–1991.Covariatesadjustedforwereage,race,smokingstatus,alcoholintake,
physical activity level, LDL cholesterol level, CRP level, and HOMO-IR. MetS, metabolic syndrome; Q, quartile.
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ﬁrst (lowest) quartile to the fourth (high-
est) quartile of total testosterone (P 
0.001), SHBG (P  0.001), CFT (P 
0.02),andCBT(P0.02)(Table1).Sim-
ilarly,thegeometricmeansoftheHOMA-IR
decreased from the ﬁrst quartile to the
fourth quartile of total testosterone (P 
0.001),SHBG(P0.001),CFT(P0.02),
and CBT (P  0.02) (Table 1).
The unadjusted prevalence of meta-
bolic syndrome steadily decreased from
the ﬁrst (lowest) quartile to the fourth
(highest) quartile of all four sex hormone
measures (all P  0.001 for linear trend
(Fig. 1). However, after adjustment for
potential confounding effects, the signiﬁ-
cantlineartrendintheprevalenceofmet-
abolic syndrome from lowest quartile to
highest quartile remained only for total
testosterone (P  0.001) (Fig. 1A) and
SHBG (P  0.004) (Fig. 1B).
The associations between the contin-
uous sex hormone indexes and metabolic
syndrome are shown in Table 2. The re-
sults indicated thata1S Dincrease in the
logarithmic value of total testosterone,
SHBG, CFT, and CBT concentration was
associatedwith17,43,7,and7%
decreases in the prevalence of metabolic
syndromeafteradjustmentforage(model
1). With Additional adjustment for race/
ethnicity, smoking status, alcohol intake,
physical activity level, LDL cholesterol,
CRP, and HOMA-IR, the associations re-
mainedsigniﬁcantonlyfortotaltestoster-
one and SHBG (model 2 and model 3).
The results of Cox regression models
with testosterones and SHBG as categori-
calvariablesandwithageadjustment(Ta-
ble2,model1)showedasigniﬁcantlinear
trend for the prevalence ratios of total tes-
tosterone (P  0.001), SHBG (P 
0.001), CFT (P  0.03), and CBT (P 
0.03) for metabolic syndrome. The age-
adjusted prevalence ratios comparing the
lowest quartile to the highest quartile
(i.e.,thereferentgroup)rangedfrom1.76
for CFT to 3.77 for total testosterone.
After additional adjustment for race/
ethnicity, smoking status, alcohol intake,
physical activity level, LDL cholesterol,
and CRP, the linear trend of the preva-
lence ratios remained statistically signiﬁ-
cant for total testosterone (P  0.01),
SHBG (P  0.001), CFT (P  0.05), and
CBT (P  0.02) (Table 2, model 2). How-
ever,afterfurtheradjustmentforHOMA-IR
(on the basis of model 2), the linear trend
oftheprevalenceratioswassigniﬁcantfor
only total testosterone (P  0.001) and
SHBG (P  0.02) (Table 2, model 3). We
replicated the analyses of model 3 in Ta-
ble 2 by replacing HOMA-IR with fasting
seruminsulinandobtainedsimilarresults
(data not shown).
Figure 2 shows the adjusted preva-
lence ratio and 95% CI of total testoster-
one, SHBG, CFT, and CBT for the ﬁve
Table 2—Prevalence ratios and 95% CI of the metabolic syndrome (as deﬁned by National Cholesterol Education Program Adult Treatment
Panel III) by the quartiles of testosterones and SHBG in U.S. men >20 years of age, NHANES III Phase I, 1988–1991
n
Prevalence ratio (95% CI)
Model 1 Model 2 Model 3
Total testosterone (nmol/l)
1 SD increase (log scale) 1,226 0.83 (0.76–0.91) 0.81 (0.73–0.89) 0.87 (0.80–0.94)
1st quartile (0.2–14.2) 351 3.77 (2.50–5.71) 3.99 (2.60–6.13) 2.16 (1.53–3.06)
2nd quartile (14.2–18.2) 308 3.99 (2.63–6.04) 4.11 (2.70–6.25) 2.51 (1.86–3.37)
3rd quartile (18.2–22.9) 289 1.37 (0.83–2.26) 1.37 (0.84–2.25) 1.24 (0.78–1.97)
4th quartile (22.9–47.0) 278 1.00 (referent) 1.00 (referent) 1.00 (referent)
P value† 0.001 0.01 0.001
SHBG (nmol/l)§
1 SD increase (log scale) 1,226 0.57 (0.52–0.64) 0.58 (0.51–0.67) 0.71 (0.60–0.82)
1st quartile (9.7–25.2) 259 3.64 (2.48–5.35) 3.32 (2.12–5.20) 2.17 (1.32–3.56)
2nd quartile (25.2–34.6) 292 2.37 (1.47–3.84) 2.18 (1.37–3.49) 1.54 (0.95–2.48)
3rd quartile (34.6–47.1) 299 1.58 (1.01–2.45) 1.53 (0.99–2.36) 1.29 (0.82–2.02)
4th quartile (47.1–198.3) 376 1.00 (referent) 1.00 (referent) 1.00 (referent)
P value† 0.001 0.001 0.02
CFT (nmol/l)‡
1 SD increase (log scale) 1,226 0.93 (0.84–1.04) 0.91 (0.82–1.02) 0.95 (0.85–1.07)
1st quartile (0.0–0.3) 397 1.76 (1.03–3.01) 1.77 (1.00–3.15) 1.18 (0.81–1.72)
2nd quartile (0.3–0.4) 279 1.61 (0.91–2.88) 1.54 (0.90–2.64) 1.13 (0.74–1.72)
3rd quartile (0.4–0.5) 255 1.39 (0.78–2.48) 1.41 (0.76–2.60) 1.20 (0.77–1.88)
4th quartile (0.5–1.1) 295 1.00 (referent) 1.00 (referent) 1.00 (referent)
P value† 0.03 0.05 0.45
CBT (nmol/l)‡
1 SD increase (log scale) 1,226 0.93 (0.84–1.03) 0.92 (0.82–1.03) 0.97 (0.85–1.09)
1st quartile (0.0–6.4) 412 2.27 (1.23–4.20) 2.17 (1.08–4.35) 1.36 (0.87–2.13)
2nd quartile (6.5–8.7) 294 2.13 (1.03–4.41) 1.95 (0.96–3.95) 1.34 (0.78–2.29)
3rd quartile (8.7–11.0) 247 1.81 (0.95–3.47) 1.79 (0.89–3.61) 1.54 (0.95–2.49)
4th quartile (11.0–24.0) 273 1.00 (referent) 1.00 (referent) 1.00 (referent)
P value† 0.03 0.02 0.26
Model 1: adjusted for age only. Model 2: adjusted for age, race, smoking status, alcohol intake, physical activity, LDL cholesterol, and CRP. Model 3: adjusted for
allcovariatesinmodel2andHOMA-IR.*Toconvertnanomolesperlitertonanogramspermilliliter,divideby3.4.†Pvalueswereestimatedinthettestofdeviation
from linear trend for the prevalence of the metabolic syndrome. ‡Estimated according to the methods proposed by Vermeulen et al. (14).
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Total testosterone was signiﬁcantly asso-
ciated with abdominal obesity (P  0.01)
and high concentrations of triglycerides
(P  0.01) (Fig. 2A). SHBG was also sig-
niﬁcantlyassociatedwithabdominalobe-
sity (P  0.001 for linear trend) and a
high concentration of triglycerides (P 
0.001) (Fig. 2B). CFT was not signiﬁ-
cantly associated with any metabolic syn-
drome components (P  0.10) (Fig. 2C).
CBT was signiﬁcantly associated with ab-
dominal obesity (P  0.04) and margin-
ally associated with high blood pressure
(P  0.07) (Fig. 2D).
We replicated the analyses after ex-
clusion of men with diagnosed diabetes
(n  60) and those with a fasting glucose
concentration 126 mg/dl (n  77). Es-
timates for the associations between sex
hormones and metabolic syndrome were
similar to that in the sample including
those with diabetes (data not shown).
CONCLUSIONS — Ourﬁndingsfrom
this large representative sample of nonin-
stitutionalized civilian adults in the U.S.
indicated that men with lower concentra-
tionsoftotaltestosteroneandSHBGhada
higher likelihood of having metabolic
syndromethanthosewithhigherconcen-
trations. This ﬁnding was independent of
traditional cardiovascular risk factors and
surrogate measures of insulin resistance.
Further, the effects of total testosterone
and SHBG on metabolic syndrome seem
to be more signiﬁcant than those of CBT
and CFT.
Because they are not bound to albu-
min and SHBG, researchers have hypoth-
esizedthatfreetestosteroneandCBTmay
be better indexes of biological activity
than total testosterone alone (18). Our
ﬁndings, however, do not support this
“free hormone” hypothesis. In our study,
total testosterone and SBHG, rather than
CFT or CBT, were independently and
strongly associated with metabolic syn-
drome.Theseﬁndingsareconsistentwith
recentreportsbyothers(10,11),inwhich
total testosterone and SHBG were found
to be signiﬁcantly related to metabolic
syndromeincidenceorprevalence,whereas
CFT was not. These population data high-
lighttheindependentandimportantroleof
SHBG in the pathogenesis of metabolic
syndrome.
As with previous studies (5), we
found that lower concentrations of total
testosterone, SHBG, CFT, and CBT were
signiﬁcantly associated with higher levels
of HOMA-IR and fasting serum insulin,
two proxy biomarkers of insulin resis-
tance. In particular, the strength of the
association between sex hormones and
metabolic syndrome decreased apprecia-
bly before and after adjustment for
HOMA-IR, suggesting that insulin resis-
tance may play a role in the observed as-
sociation. A previous study has shown
thatinsulinmaydirectlyinhibitSHBGse-
cretion from hepatoma cells in vitro (19).
In vivo studies show that insulin may
stimulate testosterone production and re-
duce SHBG concentration in both nor-
mal-weight and obese men (20).
However, polymorphisms in the SHBG
gene have recently been shown to affect
Figure 2—Prevalence ratios (PRs) and 95% CI by quartiles of total testosterone (TT) (A), SHBG (B), CFT (C), and CBT (D) for the ﬁve single
metabolic syndrome risk factors in U.S. men 20 years of age, NHANES III, Phase I, 1988–1991. Covariates adjusted for were age, race, smoking
status, alcohol intake, physical activity level, LDL cholesterol level, CRP level, and HOMO-IR. P values were obtained in t tests for the linear trends
of adjusted prevalence ratios.
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betes risks, suggesting a potential causal
role in the pathophysiological mecha-
nisms. In particular, carriers of SHBG
rs6257 allele (CC or CT) have an in-
creased risk, whereas carriers, both men
and women, of an rs6259 variant allele
(AAorAG)haveadecreasedriskoftype2
diabetes (21). Furthermore, the associa-
tion between low testosterone concentra-
tion and insulin resistance may be
partially caused by impaired Leydig cell
function (22).
Notably, total testosterone and SHBG
weresigniﬁcantlyassociatedwithabdom-
inal obesity and high triglyceride con-
centration among the ﬁve metabolic
syndrome components. Although the ex-
act mechanisms for the association re-
main unknown, observational studies
have suggested that testosterone inhibits
lipid uptake, decreases lipoprotein-lipase
activity, and reduces visceral adipose tis-
sue accumulation. In a randomized clini-
cal trial, testosterone therapy selectively
reduced visceral fat accumulation and in-
creased fat-free mass (23). On the other
hand, SHBG has been related to dyslipi-
demia, possibly by regulating hepatic li-
poprotein lipase activity and reducing the
releaseoffattyacidsfromadipocytes(24).
Furthermore, recent clinical trials have
shown that testosterone replacement
therapy signiﬁcantly reduces insulin re-
sistance and improves glycemic control
and cardiometabolic risk factors in hy-
pogonadal men with type 2 diabetes (25).
Taken together, these ﬁndings may
have signiﬁcant implications in clinical
practice. Because the total testosterone
and SHBG were associated with meta-
bolic syndrome independently of known
cardiovascular risk factors, insulin resis-
tance, and/or overall obesity, total testos-
terone and SHBG may be considered as
emerging risk factors for metabolic syn-
drome in men. Conventionally, SHBG
has not been considered as a risk factor
in the development of any diseases (i.e.,
cancer, fracture, heart disease, and type
2 diabetes) because it has been viewed
as a hormone sequester to control the
bioavailability of steroids. Our results
on the independent association of total
testosterone and SHBG with metabolic
syndrome suggest that SHBG may have
importantbiologicaleffectsinaseriesof
adverse metabolic outcomes.
Thestrengthsofourstudyincludethe
use of a large representative sample of
U.S. adult men as well as rigorous and
standardized assessment of biochemical
analyses and anthropometric indexes in
NHANES III. Our results, however, are
subject to several limitations. First, using
a cross-sectional design, we were unable
to establish a temporal sequence in the
associations among testosterones, SHBG,
and metabolic syndrome. As shown in
longitudinal studies, low total testoster-
one and SHBG concentrations predict
the occurrence of metabolic syndrome
(10,11). Conversely, individuals with di-
abetes and/or metabolic syndrome may
be more likely to have hypogonadism,
testosterone deﬁciency, or erectile dys-
function than those without. Second, we
used calculated rather than directly
measured free testosterone and bio-
available testosterone. However, previ-
ous studies have demonstrated that
calculatedfreeandbioavailableconcen-
trations are valid and reliable (14).
Third, surrogate measures of insulin re-
sistance were used in our study. Direct
measures of insulin resistance such as
steady-state plasma glucose concentra-
tion or hyperinsulinemic-euglycemic
clampmaybeusefultoreducemeasure-
ment errors.
Ourresultsdemonstratethattotaltes-
tosterone and SHBG concentrations were
strongly associated with metabolic syn-
drome independently of traditional car-
diovascular risk factors and surrogate
measures of insulin resistance. However,
CFT and CBT concentrations were asso-
ciated with metabolic syndrome but not
independently of insulin resistance. Be-
causemetabolicsyndromeandinsulinre-
sistance are risk factors for cardiovascular
diseases and type 2 diabetes, early detec-
tionofmenwithdecreasedtotaltestoster-
one and SHBG concentrations in clinical
settings will be beneﬁcial for preventing
future cardiovascular outcomes.
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